Pulxion and Medtronic Partner to Advance Innovative Health Solutions

April 23, 2025 11:00 AM AEST | By Cision

Pulxion and Medtronic Partner to Advance Innovative Health Solutions — Image source: Kalkine Media

Recent News

Collaborative Synergy: The Key to Unlocking 6G’s Potential

Bernstein upgrades Cava as it sees market overlooking its long-term gr...

Momentum Builds Towards Historic Dakar 2026 YOG

Citi cuts Texas Roadhouse stock rating on traffic slowdown, beef cost...

TAIPEI, April 23, 2025 /PRNewswire/ -- According to statistics published by the World Health Organization (WHO) in 2025, cardiovascular diseases (CVDs) are the leading cause of death globally, claiming approximately 18 million lives annually and accounting for 32% of all deaths worldwide. This highlights the crucial importance of early detection and timely management of CVDs.

Pulxion Medical Technology is dedicated to developing innovative solutions to address global health challenges, with focus on the prevention and management of cardiovascular diseases. The company aims to integrate advanced medical technologies, particularly in response to the increasing prevalence of younger patients with CVDs, such as stroke and coronary artery disease. By enabling early and rapid screening, this approach supports proactive prevention and timely intervention.

Professor Herbert Hsiao, founder of Pulxion and an esteemed professor at National Taiwan University, remarked, "Pulxion was founded with the vision of transforming traditional disease screening methods through innovative technologies, making health management simpler and more accessible. Our core product integrates advanced AI-powered video motion analysis technology to provide rapid and non-invasive disease risk assessments tailored to the needs of modern preventive healthcare, allowing more people to benefit from the convenience and efficiency of early screening."

Joy Chen, CEO of Pulxion, stated, "Pulxion continuously seeks opportunities to promote innovative solutions. Recently, we signed a Memorandum of Understanding (MOU) with Medtronic, a global leader in medical devices, establishing a strategic partnership. We plan to jointly promote Pulxion's core product in Taiwan, Hong Kong, and Macau, accelerating the adoption and application of early screening technologies. In Taiwan, Pulxion has initiated the pivotal clinical trials of our core product in major medical centers to obtain regulatory approval from the Taiwan Food and Drug Administration (TFDA)."

Pulxion Medical Technology has taken a significant step in advancing early screening for cardiovascular diseases, further strengthening its momentum toward realizing its healthcare vision of "prevention-first." Moving forward, Pulxion will continue collaborating with industry leaders to drive the adoption of innovative medical technologies, create greater value for the industry, and contribute to global health improvement.

Rapid Screening for CVDs Risk

Sources:

World Health Organization (https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1)
Ministry of Health and Welfare (https://www.mohw.gov.tw/cp-4634-52471-1.html)
Health Promotion Administration, Ministry of Health and Welfare (https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=4809&pid=18445)

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.